Gefitinib Tablets: A Revolutionary Targeted Therapy for Lung Cancer Management
1. Introduction to Gefitinib Tablets
Gefitinib, commercially known by brand names such as Gefttinat Table, is a first-generation EGFR tyrosine kinase inhibitor (EGFR-TKI). It is primarily used to treat non-small cell lung cancer (NSCLC) that has tested positive for EGFR mutations. First approved in Japan and later globally, Gefitinib represents a significant leap in cancer therapeutics due to its targeted action and minimal systemic toxicity.
Unlike older, non-specific chemotherapies that destroy all rapidly dividing cells, Gefitinib's mechanism of action allows it to selectively target and inhibit EGFR-mutant cancer cells, thereby enhancing efficacy while reducing unnecessary side effects.
________________________________________
2. How Gefitinib Works: The Science Behind the Therapy
Gefitinib belongs to the class of protein kinase inhibitors. Specifically, it blocks the ATP-binding site of the epidermal growth factor receptor (EGFR) tyrosine kinase domain. This inhibition prevents the phosphorylation and activation of EGFR, a receptor that drives the uncontrolled proliferation of cancer cells in many NSCLC patients.
Most notably, patients with exon 19 deletions or L858R mutations in exon 21 of the EGFR gene respond particularly well to Gefitinib. These mutations cause the EGFR pathway to remain overactive, promoting relentless tumor growth. Gefitinib effectively “switches off” this signaling cascade, halting tumor progression.
This targeted mechanism sets Gefitinib apart from traditional therapies, providing precision treatment with a personalized medicine approach.
________________________________________
3. Clinical Indications and Patient Suitability
Gefitinib is indicated for:
• First-line treatment of patients with locally advanced or metastatic NSCLC with EGFR-activating mutations.
• Maintenance therapy after successful response to platinum-based chemotherapy.
• In some cases, subsequent lines of treatment depending on molecular testing and patient profile.